Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01492426




Registration number
NCT01492426
Ethics application status
Date submitted
13/12/2011
Date registered
15/12/2011
Date last updated
3/06/2016

Titles & IDs
Public title
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
Scientific title
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Secondary ID [1] 0 0
2011-004237-14
Secondary ID [2] 0 0
AI444-052
Universal Trial Number (UTN)
Trial acronym
COMMAND-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daclatasvir
Treatment: Drugs - Telaprevir
Treatment: Drugs - Peginterferon alfa-2a
Treatment: Drugs - Ribavirin

Experimental: Daclatasvir + Peginterferon alfa-2a + Ribavirin -

Experimental: Telaprevir + Peginterferon alfa-2a + Ribavirin -


Treatment: Drugs: Daclatasvir
Film-coated tablet, oral, 60 mg, once daily, 24 weeks

Treatment: Drugs: Telaprevir
Film-coated tablet, oral, 750 mg, 3 times daily

Treatment: Drugs: Peginterferon alfa-2a
Solution for injection, subcutaneous injection, 180 µg, weekly

Treatment: Drugs: Ribavirin
Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
Timepoint [1] 0 0
Week 12 (Follow-up period)
Secondary outcome [1] 0 0
Percentage of Genotype 1b Participants With Rapid Virologic Response (RVR) at Week 4
Timepoint [1] 0 0
Week 4
Secondary outcome [2] 0 0
Percentage of Genotype 1b Participants With Extended Rapid Virologic Response (eRVR) at Both Week 4 and Week 12
Timepoint [2] 0 0
Week 4, Week 12
Secondary outcome [3] 0 0
Percentage of Genotype 1b Participants With Complete Early Virologic Response (cEVR)
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 24 (SVR24)
Timepoint [4] 0 0
Week 24 (Follow-up period)
Secondary outcome [5] 0 0
Percentage of Genotype 1a Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
Timepoint [5] 0 0
Week 12 (Follow-up period)

Eligibility
Key inclusion criteria
Key

* Participants chronically infected with hepatitis C virus (HCV) genotype 1a or 1b
* HCV RNA viral load =10,000 IU/mL
* No prior treatment including but not limited to interferon, ribavirin, and direct-acting antivirals
* No history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1 year
* Body mass index of 18 to 35 kg/m^2
* Negative for HIV and hepatitis B virus

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Evidence of decompensated liver disease
* Evidence of medical condition other than HCV contributing to chronic liver disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2014
Sample size
Target
Accrual to date
Final
605
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Local Institution - Camperdown
Recruitment hospital [2] 0 0
Local Institution - Penrith
Recruitment hospital [3] 0 0
Local Institution - Westmead Nsw
Recruitment hospital [4] 0 0
Local Institution - Greenslopes Qld
Recruitment hospital [5] 0 0
Local Institution - Adelaide
Recruitment hospital [6] 0 0
Local Institution - Fitzroy
Recruitment hospital [7] 0 0
Local Institution - Prahran
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2750 - Penrith
Recruitment postcode(s) [3] 0 0
2145 - Westmead Nsw
Recruitment postcode(s) [4] 0 0
4120 - Greenslopes Qld
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
3065 VIC - Fitzroy
Recruitment postcode(s) [7] 0 0
3181 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Argentina
State/province [16] 0 0
Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Austria
State/province [18] 0 0
Linz
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Brazil
State/province [20] 0 0
Sao Paulo
Country [21] 0 0
Canada
State/province [21] 0 0
Alberta
Country [22] 0 0
Canada
State/province [22] 0 0
British Columbia
Country [23] 0 0
Canada
State/province [23] 0 0
Manitoba
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Denmark
State/province [25] 0 0
Hvidovre
Country [26] 0 0
Denmark
State/province [26] 0 0
Odense
Country [27] 0 0
France
State/province [27] 0 0
Besancon
Country [28] 0 0
France
State/province [28] 0 0
Bondy Cedex
Country [29] 0 0
France
State/province [29] 0 0
Grenoble Cedex 09
Country [30] 0 0
France
State/province [30] 0 0
Lille Cedex
Country [31] 0 0
France
State/province [31] 0 0
Paris Cedex 12
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 13
Country [33] 0 0
France
State/province [33] 0 0
Pessac
Country [34] 0 0
France
State/province [34] 0 0
Strasbourg
Country [35] 0 0
Germany
State/province [35] 0 0
Berlin
Country [36] 0 0
Germany
State/province [36] 0 0
Essen
Country [37] 0 0
Germany
State/province [37] 0 0
Frankfurt
Country [38] 0 0
Germany
State/province [38] 0 0
Freiburg
Country [39] 0 0
Germany
State/province [39] 0 0
Hamburg
Country [40] 0 0
Germany
State/province [40] 0 0
Hannover
Country [41] 0 0
Germany
State/province [41] 0 0
Koeln
Country [42] 0 0
Israel
State/province [42] 0 0
Haifa
Country [43] 0 0
Israel
State/province [43] 0 0
Nazareth
Country [44] 0 0
Israel
State/province [44] 0 0
Tel Aviv
Country [45] 0 0
Israel
State/province [45] 0 0
Zefat
Country [46] 0 0
Italy
State/province [46] 0 0
Bergamo
Country [47] 0 0
Italy
State/province [47] 0 0
Cisanello (pisa)
Country [48] 0 0
Italy
State/province [48] 0 0
Firenze
Country [49] 0 0
Italy
State/province [49] 0 0
Napoli
Country [50] 0 0
Italy
State/province [50] 0 0
Torino
Country [51] 0 0
Poland
State/province [51] 0 0
Bialystok
Country [52] 0 0
Poland
State/province [52] 0 0
Chorzow
Country [53] 0 0
Poland
State/province [53] 0 0
Kielce
Country [54] 0 0
Poland
State/province [54] 0 0
Myslowice
Country [55] 0 0
Poland
State/province [55] 0 0
Raciborz
Country [56] 0 0
Poland
State/province [56] 0 0
Wroclaw
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Moscow
Country [58] 0 0
Spain
State/province [58] 0 0
Alcorcon
Country [59] 0 0
Spain
State/province [59] 0 0
Barcelona
Country [60] 0 0
Spain
State/province [60] 0 0
Valencia
Country [61] 0 0
Switzerland
State/province [61] 0 0
Zurich
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Greater London
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Scotland
Country [64] 0 0
United Kingdom
State/province [64] 0 0
West Midlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01492426